- Home
- RANI vs PULM Comparison
RANI vs PULM Comparison
Compare RANI & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANI
- PULM
- Stock Information
- Founded
- RANI 2012
- PULM 2003
- Country
- RANI United States
- PULM United States
- Employees
- RANI N/A
- PULM N/A
- Industry
- RANI Medicinal Chemicals and Botanical Products
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- RANI Health Care
- PULM Health Care
- Exchange
- RANI Nasdaq
- PULM Nasdaq
- Market Cap
- RANI 23.2M
- PULM 20.5M
- IPO Year
- RANI 2021
- PULM N/A
- Fundamental
- Price
- RANI $0.50
- PULM $4.87
- Analyst Decision
- RANI Strong Buy
- PULM
- Analyst Count
- RANI 4
- PULM 0
- Target Price
- RANI $7.75
- PULM N/A
- AVG Volume (30 Days)
- RANI 677.7K
- PULM 11.0K
- Earning Date
- RANI 08-07-2025
- PULM 11-07-2025
- Dividend Yield
- RANI N/A
- PULM N/A
- EPS Growth
- RANI N/A
- PULM N/A
- EPS
- RANI N/A
- PULM N/A
- Revenue
- RANI $1,200,000.00
- PULM $369,000.00
- Revenue This Year
- RANI N/A
- PULM N/A
- Revenue Next Year
- RANI N/A
- PULM $134.88
- P/E Ratio
- RANI N/A
- PULM N/A
- Revenue Growth
- RANI N/A
- PULM N/A
- 52 Week Low
- RANI $0.39
- PULM $1.78
- 52 Week High
- RANI $3.75
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- RANI 45.69
- PULM 44.33
- Support Level
- RANI $0.44
- PULM $4.65
- Resistance Level
- RANI $0.58
- PULM $5.00
- Average True Range (ATR)
- RANI 0.04
- PULM 0.16
- MACD
- RANI -0.01
- PULM 0.06
- Stochastic Oscillator
- RANI 32.74
- PULM 76.92
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).